Crosstalk between coagulation and complement activation promotes cardiac dysfunction in arrhythmogenic right ventricular cardiomyopathy

• Published in: Theranostics Vol. 11; no. 12; pp. 5939 - 5954
• Main Authors: Ren, Jie, Tsilafakis, Konstantinos, Chen, Liang, Lekkos, Konstantinos, Kostavasili, Ioanna, Varela, Aimilia, Cokkinos, Dennis V, Davos, Constantinos H, Sun, Xiaogang, Song, Jiangping, Mavroidis, Manolis
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01-01-2021; Ivyspring International Publisher
• Subjects: Adult; Animals; Arrhythmogenic Right Ventricular Dysplasia - immunology; Autoantibodies - immunology; Blood Coagulation - immunology; Cardiac arrhythmia; Cardiomyopathy; Complement Activation - immunology; Disease; Enzymes; Female; Heart Ventricles - immunology; Hirudins - immunology; Humans; Male; Mice; Mice, Knockout; Middle Aged; Mutation; Myocardium - immunology; Proteomics; Recombinant Proteins - immunology; Research Paper; Task forces; Thrombin - immunology; Variance analysis; Arrhythmogenic right ventricular cardiomyopathy; proteomics; complement; coagulation; serum biomarkers
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.58160

We previously found that complement components are upregulated in the myocardium of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), and inhibiting the complement receptor C5aR reduces disease severity in desmin knockout (
) mice, a model for ARVC. Here, we examined the mechanism underlying complement activation in ARVC, revealing a potential new therapeutic target.
First, immunostaining, RT-PCR and western blot were used to detect the expression levels of complement and coagulation factors. Second, we knocked out the central complement component C3 in
mice (ARVC model) by crossing
mice with
mice to explore whether complement system activation occurs independently of the conventional pathway. Then, we evaluated whether a targeted intervention to coagulation system is effective to reduce myocardium injury. Finally, the plasma sC5b9 level was assessed to investigate the role in predicting adverse cardiac events in the ARVC cohort.
The complement system is activated in the myocardium in ARVC. Autoantibodies against myocardial proteins provided a possible mechanism underlying. Moreover, we found increased levels of myocardial C5 and the serum C5a in
mice compared to wild-type mice, indicating that C5 is activated independently from the conventional pathway, presumably via the coagulation system. Crosstalk between the complement and coagulation systems exacerbated the myocardial injury in ARVC mice, and this injury was reduced by using the thrombin inhibitor lepirudin. In addition, we found significantly elevated plasma levels of sC5b9 and thrombin in patients, and this increase was correlated with all-cause mortality.
These results suggest that crosstalk between the coagulation and complement systems plays a pathogenic role in cardiac dysfunction in ARVC. Thus, understanding this crosstalk may have important clinical implications with respect to diagnosing and treating ARVC.